Literature DB >> 15011960

Recognition of classical and heavy chain forms of HLA-B27 by leukocyte receptors.

Rachel L Allen1, John Trowsdale.   

Abstract

As an MHC class I protein, the disease association of HLA-B27 with inflammatory arthritis has been widely assumed to imply a role for the T cell antigen receptor (TCR) in disease. However, in addition to their classical antigen-presenting role, HLA class I proteins are recognised by members of the killer immunoglobulin receptor (KIR) and leukocyte immunoglobulin-like receptor (LILR/ILT/LIR) families. Unusual properties of HLA-B27 include an ability of free heavy chains (FHC) to reach the cell surface in the absence of beta2m and to maintain their peptide-binding groove in vitro. This review describes immunomodulatory receptors that recognise HLA class I, and the recognition of HLA-B27 in both the classical beta2m-associated and beta2m-independent forms by members of the KIR and LILR families. Alternative recognition of different forms of HLA-B27 by leukocyte receptors could influence the function of cells from both innate and adaptive immune systems, and may indicate a role for various leukocyte populations in HLA-B27-associated inflammatory disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15011960     DOI: 10.2174/1566524043479329

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  13 in total

Review 1.  Endoplasmic reticulum aminopeptidases: Biology and pathogenic potential.

Authors:  Nigil Haroon; Robert D Inman
Journal:  Nat Rev Rheumatol       Date:  2010-06-08       Impact factor: 20.543

2.  The Authors' Reply.

Authors:  Mepur H Ravindranath; Vadim Jucaud
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

3.  Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d).

Authors:  Mitsunori Shiroishi; Kimiko Kuroki; Linda Rasubala; Kouhei Tsumoto; Izumi Kumagai; Eiji Kurimoto; Koichi Kato; Daisuke Kohda; Katsumi Maenaka
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-20       Impact factor: 11.205

Review 4.  Leukocyte immunoglobulin-like receptors in human diseases: an overview of their distribution, function, and potential application for immunotherapies.

Authors:  Jilu Zhang; Sunny Mai; Hui-Ming Chen; Kyeongah Kang; Xian Chang Li; Shu-Hsia Chen; Ping-Ying Pan
Journal:  J Leukoc Biol       Date:  2017-03-28       Impact factor: 4.962

Review 5.  HLA-B27 misfolding and spondyloarthropathies.

Authors:  Robert A Colbert; Monica L DeLay; Gerlinde Layh-Schmitt; Dawn P Sowders
Journal:  Prion       Date:  2009-01-03       Impact factor: 3.931

Review 6.  Regulation of T-cell immunity by leucocyte immunoglobulin-like receptors: innate immune receptors for self on antigen-presenting cells.

Authors:  Katie J Anderson; Rachel L Allen
Journal:  Immunology       Date:  2009-05       Impact factor: 7.397

7.  Suppression of blastogenesis and proliferation of activated CD4(+) T cells: intravenous immunoglobulin (IVIg) versus novel anti-human leucocyte antigen (HLA)-E monoclonal antibodies mimicking HLA-I reactivity of IVIg.

Authors:  M H Ravindranath; P I Terasaki; T Pham; V Jucaud; S Kawakita
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

8.  Downregulation of immunoglobulin-like transcript-4 (ILT4) in patients with psoriatic arthritis.

Authors:  Alberto Bergamini; Maria Sole Chimenti; Eleonora Baffari; Maria Domenica Guarino; Gianfranco Gigliucci; Carlo Perricone; Roberto Perricone
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

Review 9.  Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg.

Authors:  Mepur H Ravindranath; Fatiha El Hilali; Edward J Filippone
Journal:  Vaccines (Basel)       Date:  2021-06-21

10.  Ankylosing spondylitis: from cells to genes.

Authors:  José Francisco Zambrano-Zaragoza; Juan Manuel Agraz-Cibrian; Christian González-Reyes; Ma de Jesús Durán-Avelar; Norberto Vibanco-Pérez
Journal:  Int J Inflam       Date:  2013-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.